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Abstract 
During the past decade, several scales have been developed to improve the assessment of outcome in epilepsy. These 
scales were developed for adults and their reliability, validity and usefulness have been established. However, there is also a 
need for alternative measures of outcome in childhood epilepsy, especially a measure of seizure severity (SS) and measures 
pertaining to quality of life (QoL). Four of these adult scales are reviewed and compared to examine their applicability in
childhood epilepsy. Two important methodological differences between them are discussed: (a) patient self-report vs. 
physician-based scales and (b) generic vs. disease-specific nstruments. QoL in epilepsy is briefly reviewed. Severity of 
seizures and severity of side-effects are relatively neglected areas of importance toQoL in epilepsy. The existing instruments 
for adults are not appropriate for children in their present form. Some specific methodological issues, which are relevant for 
the development of scales for children with epilepsy, are subsequently discussed. New scales pertaining to physical and 
psychosocial spects of QoL in childhood epilepsy are being developed. In the near future, data on their reliability, validity 
and usefulness will become available. A combination of scales focusing on specific aspects of QoL, including SS and 
severity of adverse ffects, and more traditional clinical data may provide a more complete assessment of outcome in 
childhood epilepsy. 
Keywords: Quality of life; Outcome measure; Seizure severity; Adverse ffect; Intractable epilepsy; Children 
1. Introduction 
Traditionally, outcome assessment in epilepsy has 
pertained to seizure :frequency (SF). The limitations 
of this approach are obvious. Clearly, there are more 
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variables that may be relevant for patients with 
epilepsy. In the past decade, several health measure- 
ment instruments have been developed to improve 
assessment of outcome in epilepsy [11,23,28,71]. 
These alternative outcome measures were developed 
for adults with epilepsy. As such, they are probably 
inappropriate for children [59]. As epilepsy in child- 
hood is relatively common and not always easy to 
control, the need for improvement of traditional mea- 
sures of outcome for children with epilepsy is well 
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recognized [19,25]. We studied the relevant literature 
on outcome measures in epilepsy, as a starting point 
for the development of scales for childhood epilepsy. 
Furthermore, we explored the specific problems re- 
lating to the development of outcome measures for 
childhood epilepsy. Although a wide spectrum of 
clinical and psychosocial problems applies to pa- 
tients with epilepsy, this paper will only address the 
clinician's primary concerns in epilepsy treatment: 
seizures and adverse ffects of medication. 
Drug treatment will succeed in controlling seizures 
within a short period of time in ~ 70% of new onset 
patients [3,4,14,16]. In the remaining 30%, reason- 
able regimens fail to bring seizures under complete 
control. In 10-15%, chances of remission are ex- 
tremely poor [14,41]; these patients are often referred 
to as 'intractable' [15]. In clinical practice, the aim in 
such cases is to find the optimal balance between 
seizure suppression and adverse effects of medica- 
tion. Thus, a careful and complete assessment of the 
frequency and severity of seizures, as well as the 
prevalence and severity of side-effects, is necessary. 
2. Scales to measure the clinical severity of 
epilepsy in adults 
A comparison of four scales that have been devel- 
oped to measure the severity of seizures and adverse 
effects in adult epilepsy demonstrates quite clearly 
the different strategies in the approach to outcome 
assessment in epilepsy. We selected these scales 
because they are well described in the literature. (1) 
Two physician-based scales will be described. (2) 
Two patient-based scales will be introduced which 
have been incorporated in quality of life (QoL) 
studies. The first three scales predominantly contain 
items which are specific for epilepsy, the last is a 
more generic scale. These differences in methodol- 
ogy will be discussed in subsequent sections. 
2.1. Veterans administration (VA) rating scales for 
seizure type and frequency, neurotoxicity and sys- 
temic toxicity (VA scale) 
The VA scale provides a composite score in- 
tended to represent ' he overall effect of seizures and 
toxicity from medication on the QoL of a patient' 
[23]. It relates to SF, seizure type and severity, and 
severity of antiepileptic drug (AED) toxicity. This 
physician-based scale, developed in 1983 by Cramer 
et al., was used in an influential comparative trial of 
four AEDs [51]. A slightly modified scale has been 
validated in a Dutch population with epilepsy by 
Wijsman et al. [74]. This modified scale has been 
used for audit studies in adult epilepsy [45,75]. 
The design of the VA scale for seizure type and 
frequency reflects the idea that the three most com- 
mon seizure types in adults are not equally severe. 
Separate subscales provide ratings for generalized 
tonic-clonic seizures, complex partial seizures and 
simple partial seizures. The combination of type and 
frequency gives the basic score, with subsequent 
modifications for the presence of a useful aura, an 
avoidable precipitating factor, 'subtherapeutic' AED 
levels and specific patterns of seizures. Since seizure 
classification is a major factor in the determination 
of seizure severity (SS) in this scale, it has certain 
limitations, as discussed below (see Section 4.1). 
The VA scale has no rating for such generalized 
seizure types as absence and atonic seizures, which 
are rare in adults but not in children. 
The VA scale takes the perspective of the medi- 
cal-professional nd does not measure patient per- 
ceptions. This causes concern about the relevance of 
the scale and the validity of the complex scoring 
system. For example, in the systemic toxicity scale 
the same score is given to 'reduced platelet count 
( < 75 000)' and to 'frequent vomiting'. As far as the 
patient is concerned, these are problems with an 
entirely different impact. As such, the VA scale is 
not adequate for assessments of QoL as we would 
define it today (see Section 3.1). 
2.2. Chalfont SS scale 
This scale was designed by Duncan and Sander in 
1991 and measures only SS [28]. It is completed by 
the physician, preferably during an interview with 
the patient and an eye-witness of the seizures, as 
detailed information about the seizures is requested. 
The physician has to make a medical-professional 
distinction between different seizure types in a pa- 
tient. As in the VA scale, separate columns provide 
separate severity scores per seizure type. Individual 
item scores are modified according to the relative 
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frequency of occurrence in a seizure type (e.g. when 
incontinence occurs in 25% of seizures, the inconti- 
nence score is quartered). 
The Chalfont scale aims to measure aspects of SS 
that can be recorded objectively. Although the scale 
and weightings were based on interviews with both 
patients and their close relatives, it does not neces- 
sarily reflect he individual patient's opinion. 
To our knowledge, the Chalfont scale has not 
been validated in ch!ildren. 
2.3. Liverpool SS scale 
This epilepsy-specific scale was developed to 
measure the ('subjective') severity of seizures as 
perceived by the pal;ient, although it includes some 
'objective' items [11]. The instrument consists of 
two subscales: perception of control and ictal and 
postictal events. Mo:~t items use a simple subjective 
four-point response scale, ranging from 1 (the patient 
perceived that aspect of the seizure to be no prob- 
lem) to 4 (a severe problem). The patient may choose 
to complete different columns for his/her 'major' 
and 'minor' seizure,;. There is increasing evidence 
that this scale is reliable, valid and useful as an 
outcome measure in a clinical trial [10,68]. It has 
been included in a multidimensional model for QoL 
in epilepsy developed by Baker and colleagues [9,10]. 
Recently, a similar patient-based a verse vent pro- 
file has been developed (Baker et al., submitted for 
publication). 
Although these scales reflect the individual pa- 
tient's perception, both the Liverpool SS scale and 
the adverse vents pJFofile agree well with the clini- 
cian's paradigm of the severity of epilepsy [37]. As 
these are self-report scales for adults, they would 
have to be modified to be applicable in a childhood 
population. 
2.4. Epilepsy surget) inventory (ESI)-55 
The ESI-55 was developed by Vickrey and col- 
leagues in 1992 [71]. Like the Liverpool scales, the 
ESI-55 is a subjective patient-based scale. This self- 
report scale was dew,loped for studies assessing the 
outcome of epilepsy surgery in adults. It consists of a 
generic core (the RAND 36-Item Health Survey) 
with additional items, providing an epilepsy-specific 
supplement. The items about physical function and 
pain do not specifically address the consequences of 
seizures or antiepileptic medication. When compared 
to the Liverpool scales, the ESI-55 is a more generic 
measure of QoL and its relation to epilepsy-specific 
clinical variables, like SS and severity of adverse 
effects, is not as direct as in the Liverpool scales. 
The ESI-55 has been applied to evaluate seizure- 
based outcome systems from studies addressing the 
outcome of epilepsy surgery [72]. 
Because the ESI-55 was designed for patients 
with a severe form of epilepsy who are candidates 
for epilepsy surgery, it may not be valid for less 
severe forms of epilepsy. For this reason, the ESI-55 
was expanded for broader application as the QoL in 
epilepsy (QOLIE) scale [57]. In their present form, 
as self-report scales for adults, they are not appropri- 
ate for children with epilepsy. 
3. Definitions and basic differences in methodol- 
ogy 
The previous section has shown that there are 
important differences between existing health mea- 
surement scales for seizures and adverse ffects of 
AED. Not surprisingly, none of these scales seems 
directly suitable for use in childhood epilepsy. How- 
ever, they illustrate some important differences in 
methodology. 
First, it seems appropriate to define two terms 
associated with assessment of outcome of chronic 
disorders: QoL and clinimetrics. Two basic method- 
ological differences in the presented sample of scales 
are subsequently discussed. 
3.1. QoL 
Health-related QoL (or perceived health status) 
refers to a scientific analysis of the functional out- 
come of a disease and its treatment in a patient [63]. 
The goal is to quantify patient's perceptions as valid 
and reliable data [9]. According to Schipper et al., 
the questions included in the assessment may be 
drawn from the experience of patients, relatives and 
health care providers, but they should be answered 
from the patient's perspective [63]. Some authors, 
however, take a more restrictive - patient-centred - 
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view [34]. Karnofsky and colleagues were the first in 
the literature to demonstrate the importance of as- 
sessment of the effects of disease on a patient's 
functional status [42]. The formal use of the term 
QoL developed later and its definition is still - to 
some extent - a matter of debate. 
QoL is essentially a multidimensional concept, 
including physical, psychological, social and eco- 
nomic domains [63]. It is widely recognized as an 
important outcome measure in chronic disease [1]. 
The major drawback in the use of QoL assessments, 
is the lack of consensus on how it should be mea- 
sured [34,35] and the complexity of most attempts to 
measure it. 
3.1.1. QoL and epilepsy 
Epilepsy is a relative latecomer in the field of 
formal QoL studies [9,39]. A great deal of past 
psychosocial research on the impact of epilepsy might 
be appropriately termed 'QoL-research' [39,62]. QoL 
in epilepsy has been reviewed elsewhere 
[39,52,62,67]. From these reviews it becomes clear 
that the physical domain has been neglected as com- 
pared to the psychosocial domain. Many studies 
claiming to report QoL have only addressed psy- 
chosocial issues. Hermann identifies symptoms and 
functional status as underinvestigated areas of QoL 
in epilepsy [39]. 
As QoL is the ultimate outcome of medical treat- 
ment of any chronic disorder, there is no doubt that it 
is relevant in epilepsy and should be incorporated in
trials comparing treatment regimes [24,25,52,76]. 
3.2. Clinimetrics 
Clinimetrics refers to the use of rating scales 
which transform clinical data into a score. This 
allows the summation of different medical variables 
and, thus, facilitates tatistical comparisons of a pa- 
tient's status and the assessment of change after 
treatment [31]. This does not imply that the clinician 
is the only source of information. Clinimetric tools 
usually relate to severity of disease in medical terms, 
but can be a part of QoL research, when they 
quantify clinical data from the patient's perspective: 
a clinimetric approach to assessing QoL in epilepsy 
[22]. 
3.3. Methodological issues 
A comparison of the scales in Section 2 indicates 
that there are important methodological differences 
between them. At least, we can make a distinction 
along two axes. 
(1) Physician-based vs. patient-based scales (2.1 
and 2.2 vs. 2.3 and 2.4). 
(2) Epilepsy-specific vs. generic scales (2.1 to 2.3 
vs. 2.4). 
Clearly, two questions are of importance: 
- Who determines the clinical severity of disease: 
the doctor or the patient? 
- When should we use disease-specific s ales and 
when a (more well known) generic profile? 
3.3.1. Who determines disease severity? 
Many authors agree that the patient is the most 
important authority regarding the effects of disease 
on his/her life [24,69]. At least, doctors and nurses 
are not able to assess overall QoL of their patients in 
a meaningful and reliable way [66]. This favours the 
assessment of subjective disease severity as per- 
ceived by the patient and QoL assessments are based 
on this principle. The openly subjective nature of 
QoL assessments, however, is a source of unease 
among some investigators [63]. In the opinion of 
some authors, physician-based scales are more 'sci- 
entific' than scales reflecting patient's perceptions 
[13l. 
Perhaps, a sharp division between 'patient-based' 
and 'physician-based' scales is too artificial. Any 
health measurement scale reflects patients' as well as 
doctors' opinions both in the development and selec- 
tion of the scale as well as in the completion of the 
scale in an individual patient's case. 
3.3.2. Generic and specific scales 
Disease severity can be assessed with generic 
scales, which are broadly applicable across different 
diseases and populations, or with disease- or popula- 
tion-specific instruments [32,36,39,56]. A clear ad- 
vantage of many generic scales is that they are well 
validated. This is especially important, since for 
most health measurement scales there is no 'gold 
standard' to assess their validity in a simple way. 
However, using such generic scales, one can eas- 
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ily miss important problems that relate only to a 
specific condition. If one focuses more accurately on 
a specific disease or population, this will result in 
increased responsiveness of an scale [36]. As epilepsy 
is not an 'average' disease, we agree with others that 
at least a fair amount of epilepsy-specific tems 
should be included in any scale developed to assess 
treatment effects in clinical trials concerning epilepsy 
[67]. 
4.  Ep i lepsy -spec i f i c  sca les :  se i zures  and  adverse  
e f fec ts  
As the severity of uncontrolled epilepsy depends 
to a large extent on the frequency and severity of 
seizures and side-effects of AEDs, these variables 
should be addressed adequately in epilepsy-specific 
scales. 
4.1. SF and type 
Most clinical trials in intractable epilepsy are 
based on an assessment of change in SF. However, 
there is no consensu,; on how a change in SF should 
be measured or reported. A large number of different 
outcome systems, typically classifying patients into 
categories relating to SF, is used [5,23,72]. For some 
seizure types, reporls of SF may be unreliable as 
they are difficult to quantify without sophisticated 
techniques [30]. 
The outcome systems used in most studies fail to 
recognize that the consequences of seizures deter- 
mine the number of attacks which an individual 
patient will tolerate. At least for patients with several 
'minor seizures' a day, the absolute quantity of 
seizures may not be clinically relevant, nor would a 
reduction in SF of 50% be very significant 
[15,60,65,72]. 
4.2. Seizure type and severity 
both classification and SS. However, the ILAE 
seizure classification [20] is not a complete and 
sensitive indicator of SS. 
- Its lacks content validity for this purpose: many 
factors that intuitively are relevant o SS, are not 
included: incontinence, injuries, postictal dysfunction 
etc. 
- It lacks discriminative ability: within one seizure 
type, factors relating to severity may vary, e.g. a 
complex partial seizure lasting 15 s is less severe 
than a complex partial seizure lasting 8 min, despite 
identical classification. 
- It is not adequately sensitive to change in SS: a 
change of SS can only be monitored if it results in a 
change in classification. 
- It is not as practical as it might seem. Espe- 
cially, in the more complex childhood epilepsies 
seizure classification is not a simple matter [73]. 
In conclusion, for studies of uncontrolled epilepsy, 
a combination of a measure of SF and seizure classi- 
fication is not sufficient. The development of a 
complete seizure-based outcome system should in- 
clude a specific measure of SS. 
In Section 2, we reviewed two scales, providing 
such a measure of SS: the Chalfont and the Liver- 
pool SS scales (Section 2.2Section 2.3, respectively). 
Both scales include to a large extent he same vari- 
ables, as shown in Table 1. 
According to Cramer, the major problems inher- 
ent in assessing SS are dependence on patient recall 
and reporting, and observer documentation [22]. 
4.3. Timing, predictability and control of seizures 
The VA and Chalfont scales include modifying 
factors for timing and/or predictability. The Liver- 
pool SS scale has a subscale for this construct (Table 
1), although it is less reliable and sensitive than the 
ictal subscale [68]. The common idea is that some 
degree of predictability and control makes seizures 
less likely to cause injuries and perhaps less severe. 
SF is quite meaningless without at least informa- 
tion about seizure type. Clinicians will have some 
idea of the average severity of different seizure 
types. For example, seizure duration, an obvious 
indicator of SS, is related to seizure type [47,73]. 
Loss of consciousness during a seizure influences 
4.4. Adverse effects of antiepileptic drug treatment 
At present, in most studies, reports of adverse 
effects are descriptive and lack quantification [46,50]. 
Assessment of adverse ffects is of great importance 
in epilepsy treatment [10,33,41,48]. Considerations 
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Table l 
Comparison ofvariables included in two scales measuring SS 
Liverpool SS scale Chalfont SS scale 
Perception subscale 
Timing 
Aura 
Predictability 
Prevention 
Clustering 
Control 
Day-to-day activity 
Occurrence in sleep 
lctal and postictal subscale 
Overall severity of seizures 
Loss of consciousness 
Duration of loss of 
consciousness 
Lip-smacking/fidgeting 
Postictal confusion 
Duration of postictal 
confusion 
Falling 
Headache 
Incontinence 
Tongue-biting 
Warning before loss of 
awareness 
Nocturnal seizures only: 
divide score by 2 
Loss of awareness 
Duration of seizure 
Automatisms 
Time to return to normal 
from onset 
Fall to ground 
Incontinence 
Injury, including 
tongue-biting 
Drop, spill a held object 
Convulsion (clonic jerking 
of limbs) 
regarding adverse effects influence the selection of 
an AED regimen [18,38,48,51,70]. Adverse effects 
are associated with high doses and the use of multi- 
ple AEDs [48,58]. Thus, patients with uncontrolled 
seizures are at risk for adverse effects, as they are 
often prescribed high doses or a combination of 
AEDs [64]. 
It is possible to classify adverse effects along 
different axes, such as relationship to duration of 
therapy (early vs. late adverse ffects) or relationship 
to dose (idiosyncratic vs. dose-dependent adverse 
effects) or by organ system [26]. The most frequent 
adverse effects are dose-related, not dangerous and 
quite subjective [48]. They may come and go when 
the dose is changed or when the patient's tolerance 
to the drug changes [29]. Therefore, an individual, 
subjective measure for these 'subtle' adverse effects 
seems useful. Clinically severe adverse effects are a 
rare and clear medical-professional problem and the 
patient's perception in such cases is less relevant. 
Behavioural and cognitive adverse ffects are usually 
evaluated with standardized psychological tests 
[2,53]. As these psychological tests are not easily 
administered, especially in children, a more simple 
(screening) tool may be useful [21]. 
5. Health measurement scales in childhood 
epilepsy 
It is not surprising that health measurement scales 
developed for an adult population are seldom appro- 
priate for children [59]. We concluded that the re- 
viewed scales for adult epilepsy patients in their 
present form are inappropriate for childhood epilepsy. 
Let us look at the reasons for this conclusion and at 
some specific issues relating to scales for children 
and childhood epilepsy. 
5.1. Who determines disease severity in children? 
Children are a problematic group for self-report 
scales. Self-report scales for children require separate 
scales at least for different age groups. Probably, sex 
groups should be analysed separately at different 
developmental stages, as during the school age pe- 
riod, girls may have relatively superior language and 
social skills [43]. All this makes it difficult to com- 
pare results. 
Second, any researcher developing a self-report 
scale for children should be aware of their struc- 
turally different way of thinking about disease [44]. 
A model of severity of epilepsy that makes sense to 
adults, may not agree with the ideas that children 
have. 
Third, for children who develop epilepsy, the 
parents play a crucial role in relation to rationaliza- 
tion and, as suggested by Scambler, the opinions of 
young children about their epilepsy may in fact be 
very similar to their parents' opinions [61]. This 
raises the question: Is it worthwhile developing a 
childhood self-report scale if the same information 
can be collected more easily by questioning the 
parents? 
In most studies on disease severity in children, 
information comes from the parents, even when the 
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aim is to assess the children's QoL [59]. Apparently, 
many researchers believe that the parents are so 
close to their child that their perception of disease 
severity approaches the child's perspective. Further- 
more, such an approach rightly recognizes parents as 
experts on their own children [54]. Self-report scales 
in childhood epilep:~y are usually aimed at adoles- 
cents. Ratings by adolescents and their parents may 
well disagree [7]. 
When subjective assessments of disease severity 
are used, one must consider the possibility of biased 
assessments. For exztmple, when parents are asked to 
quantify the severity of specific aspects of a child's 
epilepsy, they may be biased by the overall disease 
severity and may have difficulties to focus on the 
specific issue addressed in a scale. Anxiety and 
coping difficulties may bias ratings by the parents in 
severe cases of epilepsy. In some cases, clinicians 
may feel the parents have produced 'idiosyncratic' 
scores, which are tetally out of line with the clini- 
cian's view. Health measurement scales are to be 
used to supplement the standard clinical information 
and results should always be interpreted in this con- 
text. Nevertheless, it is not always within the physi- 
cian's competence to judge at what point ratings by 
the parents become exaggerated and such a conclu- 
sion should, therefore, be reached with caution. 
5.2. Specific characteristics of childhood epilepsy 
The need for a clhildhood epilepsy-specific s ale 
is further emphasized by the following specific char- 
acteristics of childhood epilepsy. 
Childhood epilepsy is often more complex than 
adult epilepsy. Children with chronic epilepsy fre- 
quently have polymorphous seizure disorders. 
Predictability and control of seizures may also be 
relevant issues in childhood seizures. However, a 
warning signal for a seizure may not be as useful in 
children as in adult patients, as children, especially 
those who are retarded, may be less able to take 
appropriate action. 
Many children with chronic epilepsy are mentally 
retarded or have other impairments [12,41]. In poly- 
handicapped patients, it is more difficult to deter- 
mine to what extent the epilepsy contributes to the 
overall impairment [27]. 
The incidence and nature of adverse effects re- 
ported in children are different from those in adults 
[49,70]. A scale to assess the presence and severity 
of adverse effects of AEDs in children should be 
adjusted to the specific characteristics of adverse 
effects in this population. 
Daily life and responsibilities in children are 
clearly different from those of adults and, thus, the 
consequences of seizures are different [55]. Hence, 
the extent o which epilepsy is a handicapping disor- 
der or causes disabilities [77] differs in adults and 
children. 
6. Development of improved outcome measures 
for childhood epilepsy: on-going projects 
Most research into improvement of outcome as- 
sessment and QoL in childhood epilepsy is of very 
recent date and only preliminary reports are avail- 
able. Studies addressing QoL are focused on psy- 
chosocial, rather than physical or clinical factors. For 
this reason, a discussion of projects addressing phys- 
ical aspects of QoL in childhood epilepsy has to be 
brief. 
Baker et al. proposed a multidimensional model 
to assess QoL in childhood epilepsy, including mea- 
sures of SS, severity of adverse effects, mood and 
behaviour, intellectual function and physical co- 
ordination [9]. A questionnaire based on this model 
was used in a study of lamotrigine in children with 
severe pilepsy and learning difficulties (Baker, writ- 
ten communication). 
In 1993, the Dutch Study Group of Epilepsy in 
Childhood has embarked on a project to improve 
outcome assessment in childhood epilepsy. It was 
decided to focus on the physical domain of QoL, 
specifically on SS and severity of adverse effects. 
Subjective parent-completed scales were developed 
[78]. Furthermore, a scale was developed to measure 
the severity of disabilities due to restrictions in activ- 
ities of daily life [17]. 
Austin et al. have compared the QoL of children 
with asthma nd children with epilepsy, using more 
generic and predominantly psychosocial measures 
[8]. Children with epilepsy had a more compromised 
QoL in the psychological, social and school domain, 
and children with asthma in the physical domain. By 
Austin and Austin, social activities and parental su- 
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pervision of children with new-onset epilepsy were 
studied [6]. Reduced child activity was found to be 
related to SF. 
Hoare and Russel published a pilot validation 
study using a newly developed parental QoL ques- 
tionnaire measuring the impact of illness on children 
with epilepsy and their famil ies [40]. No data to 
support the scale's reliability were given. Their scale 
reflects a generic approach, as it was intended to be 
valid for children with other disabilities as well. 
In conclusion, the perfect assessment of  outcome 
in chi ldhood epilepsy will perhaps never be achieved, 
but in our opinion a combination of well  validated 
and reliable measures pertaining to specific physical 
and psychosocial aspects of  QoL, with medical-pro- 
fessional outcome variables in epilepsy, would seem 
an important step forward. In the near future, such 
new measures of outcome will become available. 
However,  the final proof  of  their usefulness must 
come from clinical trials. 
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